Core Viewpoint - Baiotai has received FDA approval for BAT2206 (Ustinumab) injection, indicating a significant milestone for the company in the biopharmaceutical sector [1] Group 1: Product Approval - The FDA has approved BAT2206 (Ustinumab) injection, marketed in the U.S. as STARJEMZA [1] - The drug is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, moderate to severe active Crohn's disease, and moderate to severe active ulcerative colitis in both adults and children [1] Group 2: Commercialization Efforts - Baiotai is actively pursuing the commercialization of BAT2206 in multiple global regions [1] - The company has submitted marketing authorization applications to the NMPA in China and the EMA in Europe [1]

Core Insights - The article emphasizes the global expansion strategy of companies listed on the Sci-Tech Innovation Board, highlighting their commitment to innovation and open collaboration in the face of globalization challenges [1][7]. Group 1: Overseas Revenue Growth - In 2024, nearly 80% of Sci-Tech Innovation Board companies achieved overseas sales, with total overseas revenue reaching 430.36 billion yuan, accounting for 30% of the board's total operating income [2]. - The overseas revenue grew by 6.1% year-on-year, outpacing the overall revenue growth of the board, indicating a successful strategy to tap into international markets [2]. - Approximately 40% of companies reported a year-on-year increase in overseas revenue that exceeded their overall revenue growth, with 173 companies seeing overseas revenue growth of over 30% [2]. Group 2: Market Penetration and Product Reach - 63 companies exported products to over 50 countries, with 25 companies achieving sales in more than 100 countries [2]. - Notable examples include Kingsoft Office, which serves over 220 countries with 630 million monthly active devices, and BeiGene, whose drug has been approved in 45 markets [2]. Group 3: Competitive Positioning and Innovation - 37 companies ranked first globally in terms of shipment volume, market share, and sales in their respective fields, indicating strong market penetration [3]. - Companies like Shanghai United Imaging Healthcare have established a significant presence in over 13,000 medical institutions globally, while LalaPlus has seen a dramatic increase in overseas revenue from 2.845 million yuan in 2023 to 72.252 million yuan in 2024 [3]. Group 4: Mergers and Acquisitions - Since the introduction of the "Sci-Tech Innovation Board Eight Articles" in June 2024, 14 cross-border acquisition transactions have been initiated by listed companies [3]. - Notable acquisitions include Suzhou MicroPort's purchase of a 51% stake in Creo Medical and Suzhou Haocen's acquisition of CadLine, enhancing their international market reach [3]. Group 5: High Margin Products and Intellectual Property - The median gross margin for overseas sales of Sci-Tech Innovation Board companies reached 40.8%, surpassing the overall gross margin of the board [4]. - Companies are leveraging patented technologies for international expansion, with 10 innovative drug companies licensing their products to foreign firms [4][5]. Group 6: Global Value Chain Reconstruction - Companies are focusing on the upstream of the value chain, redefining international competition through technological innovation [4]. - 58 companies have taken the lead in setting international standards in their fields, enhancing their influence within the industry [5][6]. Group 7: Localized Production and Employment - 110 companies have established production capacities in 37 countries, contributing to local economic development [7]. - Companies like Transsion Holdings have set up factories in various countries, creating significant employment opportunities [7]. Group 8: Contribution to Global Initiatives - Several companies are actively participating in the Belt and Road Initiative, promoting advanced manufacturing and public health solutions in various countries [8]. - Examples include SANY Heavy Industry's factory in Indonesia and Haier Biomedical's solar-powered cold storage solution in Nigeria [8].